Developed Formulas
  • Controls cholesterol levels
  • Regulates triglyceride levels
  • Controls LDL oxidation levels
  • Enhances CLA (Conjugated Linoleic Acid) production
Clinical test
In vitro test
Hydrosoluble powder
Allergen Free

Bifidobacterium lactis MB2409 (DSM 23733)
Bifidobacterium bifidum MB109 (DSM 23731)
Bifidobacterium longum 04 (DSM 23233)

Label Claim

Food supplement with probiotic strains

Effective nutraceutical combination

EFSA Claim: contributes to normal lipid metabolism (82.5 mg)
Plant sterols
EFSA Claim: contributes to the maintenance of normal blood cholesterol levels (800 mg)

Scientific Rationale

Cardiovascular disease (CVD) is one of the major health issues with a high mortality rate (~17.7 million deaths/year, which rose by 12.5% since 2005) [1]. Epidemiological studies confirmed the correlation between total cholesterol (TC) with increased cardiovascular risk [2]. BIFISTEROL® Junior contains three Bifidobacterium strains specifically isolated and studied for their cholesterol-lowering effects which has been confirmed by in vitro, preclinical and clinical studies [3-5]. The strains activity on cholesterol levels can be partially ascribed to:

  • BSH (Bile Salts Hydrolyses) activity, which results in deconjugation of bile salts that are less efficiently reabsorbed than their conjugated counterparts. Deconjugation of bile salts can co-adjuvate for reduction in serum cholesterol either by increasing the demand for cholesterol for de novo synthesis of bile acids or by reducing cholesterol solubility and thereby absorption of cholesterol throughout the intestinal lumen.

  • Binding of cholesterol to the bacterial cell walls that can’t be reabsorbed and is lost through feces.

  • Moreover, B. longum 04 is a strong converter of linoleic acid (LA) into conjugated linoleic acids (CLA) [6]. CLA has been found to be effective in regulating cholesterol homeostasis, contrasting atherosclerotic damages, and maintaining cardiovascular function, reducing body fat, and positively affecting blood lipids in animals and in vitro models.

In a double-blind, crossover, placebo-controlled RCT [5], a 3 months supplementation of BIFISTEROL® Junior was effective in improving the lipidic profile in children with dyslipidemia compared to placebo. Indeed, BIFISTEROL® Junior reduced total cholesterol (TC), triglycerides (TG) and low-density lipoprotein cholesterol (LDL-C), and increased high-density lipoprotein cholesterol (HDL-C).


1. ​​Benjamin EJ,... American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67–e492. doi:10.1161/CIR.0000000000000558.

2. Jeong SM, et al. Effect of change in total cholesterol levels on cardiovascular disease among young adults. J Am Heart Assoc. 2018;7(12):e008819. doi:10.1161/JAHA.118.008819.

3. Mogna L, Mogna G. Innovative probiotics and systemic bioactive metabolites. Anti-ageing potential. Nutrafoods. 2012;11:151–164. doi:10.1007/s13749-012-0057-4.

4. Bordoni, et al. Cholesterol-lowering probiotics: in vitro selection and in vivo testing of Bifidobacteria. Appl Microbiol Biotechnol. 2013;97:8273-8281. doi:10.1007/s00253-013-5088-2.

5. Guardamagna O, et al. Bifidobacteria supplementation: effects on plasma lipid profiles in dyslipidemic children. Nutrition. 2014 Jul-Aug;30(7-8):831-6. doi:10.1016/j.nut.2014.01.014.

6. Internal Probiotical data